The Board of the company currently consists of one executive member and six non-executive members, each of whom is considered by the Board to be independent in character and judgment. The Board performs regular reviews of its composition as to background, function and experience, in order to ensure diversity and to balance knowledge of Idorsia’s business with fresh perspectives.

Board of Directors

Mathieu Simon

Date of birth: 6 May 1956

Nationality: French

Show more

Education: Université de Paris (Paris 7).

Professional background: Former Chairman of the Board of Cellartis AB; Executive Vice-President, Chief Operating Officer of Cellectis Group, CEO of Cellectis Therapeutics and CEO of Ectycell; Managing Director, Head of Global Pharma Operations at Pierre Fabre SA: various management and EU regional management roles as well as senior corporate functions at Wyeth Pharmaceuticals.

Other activities and functions: Member of the Board of Directors of two listed companies, Affimed, and Lysogene, and of three unlisted companies, BB Pureos Bioventures, LNC SA, and Messier Maris & Associés. Advisor at the EU Commission (Horizon 2020 Program).

Show less

Date of birth: 22 February 1950

Nationality: German

Show more

Education: Business degrees from the European Business School and Harvard Business School (Advanced Management Program)

Professional background: CEO of Nasdaq-listed uniQure N.V.; President and CEO of Evotec AG; former Chairman of Molecular Partners.

Other activities and functions: CEO of the listed company Hookipa Pharma Inc.; Member of the Board of Directors at the listed company Unum Therapeutics.

Show less

Date of birth: 3 April 1955

Nationality: Swiss and French

Show more

Education: Medical degree in France; further training in pharmacology and physiology at the University of Montreal, Canada, and the University of California, San Francisco, US.

Professional background: Practicing cardiologist, 1980–1985. Head of Drug Discovery Group in the Cardiovascular Department of F. Hoffmann-La Roche, 1985–1997. Founder and CEO of Actelion, 1999–2017.

Other activities and functions: None.

Show less

Date of birth: 18 February 1951

Nationality: French

Show more

Education: École des hautes études commerciales (HEC) and the École nationale d’administration (ENA).

Professional background: Chairman and CEO at Eutelsat; Chairman and CEO of ViroPharma; Chairman and CEO of Rhône Poulenc Rorer and Rhône-Poulenc Santé; Various positions in the Poulenc Group; Auditor at the French Ministries of Finance and Defense.

Other activities and functions: Chairman of the Board at three listed companies, two clinical-stage biopharmaceutical companies DBV Technologies and Pharnext; and Faurecia.

Show less

Date of birth: 26 February 1957

Nationality: Swiss

Show more

Education: Doctorate in law from the University of Zurich and a Master of Laws in Business and Taxation (Transnational Practice) from the McGeorge School of Law, Sacramento, California; further education at Harvard Business School.

Professional background: Former General Counsel and a member of the Executive Committee of Novartis; Executive Chairman of the Board at Bär & Karrer.

Other activities and functions: Serving on the Board of Directors of several listed and non-listed companies, most notably as Chairman of the Board at the unlisted Globalance Bank AG and as a Board Member and Audit Committee Chair at the listed company Geberit AG; Member of the Board of the Law and Economics Foundation at the University of St. Gallen.

Show less

Date of birth: 24 January 1965

Nationality: American

Show more

Education: Master of Laws degrees from Cornell University and New York University, and is a member of the New York State Bar.

Professional background: Senior Vice President at Celgene; Senior roles in business development and tax at Pfizer; advising multinational corporations at Ernt & Young.

Other activities and functions: Chief Financial Officer and Chief Business Officer at the listed company Sarepta Therapeutics; Member of the Board of Directors of two listed companies, Flexion Therapeutics, Inc. and Aeglea BioTherapeutics, Inc.

Show less

Date of birth: 15 October 1963

Nationality: French

Show more

Education: MBA, Ecole Supérieure de Commerce de Paris.

Professional background: Held various executive positions such as Head of Finance and Control NBE at Nestlé, Group CFO of Galderma, Global Pharma Business unit CFO and EMEA CFO at Wyeth, Global Division CFO at Novartis OTC. 

Other activities and functions: Member of the Board of Directors of three listed companies, UCB, Voluntis SA, and DBV Technologies, and one unlisted company, Novo Holdings.

Show less

Elections and Terms of Office

Under Articles 13 and 16 of the Articles of Association, the 3–9 members of the Board of Directors are elected individually by the General Meeting of the Shareholders for a term of office corresponding to the legally permitted maximum term of one year. One year of office is understood to be the period from one ordinary Meeting of the Shareholders to the next ordinary Meeting of the Shareholders.

Time of First Election and Remaining Term of Office

  Executive
Member
Date of AGM of first election Date of AGM of end of term
Mathieu Simon No 2019 2021
Joern Aldag No 2020 2021
Jean-Paul Clozel Yes 2017 2021
Michel de Rosen No 2020 2021
Felix R. Ehrat No 2020 2021
Sandy Mahatme No 2020 2021
Viviane Monges No 2018 2021